New Breast Cancer Treatment Test Gets FDA Approval
A new genetic test which identifies breast cancer patients who will respond to a powerful cancer-fighting drug has won Food and Drug Administration approval.
The Spotlight HER2 CISH test, made by Invitrogen Corp. can determine whether a cancer patient is a good candidate for Herceptin, a cancer-fighting drug which destroys cancer cells in patients who have a specific cancer-promoting gene. About one in five breast cancer patients have the gene and are good candidates for Herceptin treatment.
Doctors can use the Spotlight HER2 CISH test to find out if a patient will respond to Herceptin treatment.
No related posts.